Cargando…

Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition

Detalles Bibliográficos
Autores principales:	Schaer, David, Li, Yanxia, Castaneda, Stephen, Inigo, Ivan, Surguladze, David, Xu, Xiaohong, Nugent, Desiree, Murphy, Mary, Hall, Gerald, Benhadji, Karim, Guba, Susan, Li, Yiwen, Kalos, Michael, Driscoll, Kyla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652527/ http://dx.doi.org/10.1186/2051-1426-3-S2-P402

Ejemplares similares

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
por: Holmgaard, Rikke B., et al.
Publicado: (2018)

Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
por: Giannelli, Gianluigi, et al.
Publicado: (2020)

Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
por: Giannelli, Gianluigi, et al.
Publicado: (2021)

Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
Publicado: (2020)

Galunisertib Exerts Antifibrotic Effects on TGF-β-Induced Fibroproliferative Dermal Fibroblasts
por: Peterson, Joshua M., et al.
Publicado: (2022)

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
por: Melisi, Davide, et al.
Publicado: (2021)

A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
por: Kelley, R.K., et al.
Publicado: (2019)

The TGFβ type I receptor TGFβRI functions as an inhibitor of BMP signaling in cartilage
por: Wang, Weiguang, et al.
Publicado: (2019)

NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF-β receptor blocker galunisertib in HCC
por: Cao, Yuan, et al.
Publicado: (2017)

Molecular characterization and expression of TGFβRI and TGFβRII and its association with litter size in Tibetan sheep
por: Zhang, Junxia, et al.
Publicado: (2023)

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
por: Herbertz, Stephan, et al.
Publicado: (2015)

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor
por: Yingling, Jonathan M., et al.
Publicado: (2017)

Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts
por: Maier, Armin, et al.
Publicado: (2015)

Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients
por: Serova, Maria, et al.
Publicado: (2015)

EPRS1 Controls the TGF-β Signaling Pathway via Interaction with TβRI in Hepatic Stellate Cell
por: Yoon, Ina, et al.
Publicado: (2023)

Focal adhesion molecule Kindlin-1 mediates activation of TGF-β signaling by interacting with TGF-βRI, SARA and Smad3 in colorectal cancer cells
por: Kong, Jinfeng, et al.
Publicado: (2016)

PGC-1α Suppresses the Activation of TGF-β/Smad Signaling via Targeting TGFβRI Downregulation by let-7b/c Upregulation
por: Choi, Hoon-In, et al.
Publicado: (2019)

Targeting TGFβR2‐mutant tumors exposes vulnerabilities to stromal TGFβ blockade in pancreatic cancer
por: Huang, Huocong, et al.
Publicado: (2019)

Emdogain-Regulated Gene Expression in Palatal Fibroblasts Requires TGF-βRI Kinase Signaling
por: Stähli, Alexandra, et al.
Publicado: (2014)

Structure-Guide Design and Optimization of Potential Druglikeness Inhibitors for TGFβRI with the Pyrrolopyrimidine Scaffold
por: Meng, Dan, et al.
Publicado: (2022)

Variances in the mRNA expression profile of TGF-β1–3 isoforms and its TGF-βRI–III receptors during cyclosporin a treatment of psoriatic patients
por: Michalska-Bańkowska, Anna, et al.
Publicado: (2018)

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine
por: Capper, David, et al.
Publicado: (2017)

SENP5 mediates breast cancer invasion via a TGFβRI SUMOylation cascade
por: Cashman, Rivki, et al.
Publicado: (2014)

Exon skipping of TGFβRI affects signalling and ECM expression in hypertrophic scar-derived fibroblasts
por: Raktoe, Rajiv S, et al.
Publicado: (2020)

Estradiol Ameliorates Acute Kidney Ischemia-Reperfusion Injury by Inhibiting the TGF-βRI-SMAD Pathway
por: Ren, Lian, et al.
Publicado: (2022)

LncRNA LITATS1 suppresses TGF‐β‐induced EMT and cancer cell plasticity by potentiating TβRI degradation
por: Fan, Chuannan, et al.
Publicado: (2023)

TGFβ-mediated expression of TGFβ-activating integrins in SSc monocytes: disturbed activation of latent TGFβ?
por: van Caam, A., et al.
Publicado: (2020)

ST3GAL5‐catalyzed gangliosides inhibit TGF‐β‐induced epithelial‐mesenchymal transition via TβRI degradation
por: Zhang, Jing, et al.
Publicado: (2022)

miR-27a inhibits cervical adenocarcinoma progression by downregulating the TGF-βRI signaling pathway
por: Fang, Fang, et al.
Publicado: (2018)

Liberating TGFβ
por: Leslie, Mitch
Publicado: (2007)

TGF-β Signaling
por: Tzavlaki, Kalliopi, et al.
Publicado: (2020)

Radiosensitizing effect of galunisertib, a TGF-ß receptor I inhibitor, on head and neck squamous cell carcinoma in vitro
por: Jank, Bernhard J., et al.
Publicado: (2022)

Fortilin interacts with TGF-β1 and prevents TGF-β receptor activation
por: Pinkaew, Decha, et al.
Publicado: (2022)

Alternative splicing of TGF-betas and their high-affinity receptors TβRI, TβRII and TβRIII (betaglycan) reveal new variants in human prostatic cells
por: Konrad, Lutz, et al.
Publicado: (2007)

Convergent evolution of a parasite-encoded complement control protein-scaffold to mimic binding of mammalian TGF-β to its receptors, TβRI and TβRII
por: Mukundan, Ananya, et al.
Publicado: (2022)

Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer
por: Gueorguieva, Ivelina, et al.
Publicado: (2016)

Radiotherapy Suppresses Angiogenesis in Mice through TGF-βRI/ALK5-Dependent Inhibition of Endothelial Cell Sprouting
por: Imaizumi, Natsuko, et al.
Publicado: (2010)

Anti-Fibrosis Effects of Magnesium Lithospermate B in Experimental Pulmonary Fibrosis: By Inhibiting TGF-βRI/Smad Signaling
por: Luo, Xin, et al.
Publicado: (2021)

Role of TGF-β 1 and TGF-β Type II Receptor in Gastric Cancer
por: Park, Dong Il, et al.
Publicado: (2002)

Genotype-Specific Interaction of Latent TGFβ Binding Protein 4 with TGFβ
por: Lamar, Kay-Marie, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5ne0kpkpqigpachqclrv3mkfjs